Niroshana Anandasabapathy

Associate Professor of Dermatology

Weill Cornell Medical College
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Niroshana Anandasabapathy is an Associate Professor of Dermatology at Weill Cornell Medical College in the United States. Her research primarily focuses on immune evasion mechanisms of the Vaccinia Virus and the aspects that contribute to successful long-term protective immunity. She is actively involved in advancing the understanding of dermatological immunology through her recent scholarly articles.

Articles (5)

Year:

2026

Year:

2026

Year:

2026

New approaches that generate long-lasting therapeutic responses in patients with therapy-resistant metastatic cancer are urgently needed. To address this challenge, we developed Spot Neoantigens in Metastases (SpotNeoMet), a novel data-driven pipeline that systematically identifies recurrently presented neopeptides in treatment-resistant patients. We identified seven therapy resistance mutations predicted to produce neopeptides presented by common HLAs. Using HLA immunopeptidomics, we discovered three novel neopeptides derived from androgen receptor (AR) H875Y, a common metastatic castration-resistant prostate cancer (mCRPC) mutation. We validated these neoantigens as highly immunogenic and then isolated and characterized cognate T-cell receptors (TCR) from healthy donor peripheral blood mononuclear cells. We demonstrated that AR H875Y–specific TCRs are highly specific and kill prostate cancer cells presenting AR neopeptides in vitro and in vivo . Our new pipeline identifies novel immunotherapy targets and potential treatment options for patients with mCRPC. Moreover, SpotNeoMet offers a systematic route to identify “HLA–peptide” pairs and their cognate TCRs across treatment-resistant cancers. Significance: As the emergence of resistance to targeted treatments in patients with metastatic cancer, there is an urgent need for innovative therapeutic approaches for this population. Our study provides a new analytic framework to identify neoantigens from treatment-resistant mutations and a proof-of-concept T cell–based immunotherapy treatment for mCRPC.

Year:

2026

Vaccinia virus is the most successful vaccine in human history and functions as a protective vaccine against smallpox and monkeypox, highlighting the importance of ongoing research into vaccinia due to its genetic similarity to other emergent poxviruses. Moreover, vaccinia’s ability to accommodate large genetic insertions makes it promising for vaccine development and potential therapeutic applications, such as oncolytic agents. Thus, understanding how superior immunity is generated by vaccinia is crucial for designing other effective and safe vaccine strategies. During vaccinia inoculation by scarification, the skin serves as a primary site for the virus–host interaction, with various cell types playing distinct roles. During this process, hematopoietic cells undergo abortive infections, while non-hematopoietic cells support the full viral life cycle. This differential permissiveness to viral replication influences subsequent innate and adaptive immune responses. Dendritic cells (DCs), key immune sentinels in peripheral tissues such as skin, are pivotal in generating T cell memory during vaccinia immunization. DCs residing in the skin capture viral antigens and migrate to the draining lymph nodes (dLN), where they undergo maturation and present processed antigens to T cells. Notably, CD8+ T cells are particularly significant in viral clearance and the establishment of long-term protective immunity. Here, we will discuss vaccinia virus, its continued relevance to public health, and viral strategies permissive to immune escape. We will also discuss key events and populations leading to long-term protective immunity and remaining key gaps.

Year:

2024

Collaborators (21)

Roni Oren

Head of Patient Derived Xenograft (PDX) Service and Human Tissue Samples Bank

Weizmann Institute of Science

ISRAEL
View details

Olga Troyanskaya

Professor

Princeton University

UNITED STATES
View details

Francisco Martínez-Jiménez

Group Leader

Vall d'Hebron Institute of Oncology

SPAIN
View details

David A. Quigley

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Eliezer Van Allen

Professor

Harvard University

UNITED STATES
View details

Raghu Kataru

Senior Research Scientist

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Alexander W. Wyatt

Assistant Professor

The University of British Columbia

CANADA
View details

Aimee S. Payne

Herbert and Florence Irving Professor and Chair

Columbia University

UNITED STATES
View details

Shifra Ben-Dor

Senior Staff Scientist

Weizmann Institute of Science

ISRAEL
View details

Tamia A. Harris‐Tryon

Vice Chair and Associate Professor

University of Texas Southwestern Medical Center

UNITED STATES
View details

Sancy Leachman

Oregon Health & Science University

UNITED STATES
View details

William Shipman

Yale University School of Medicine

UNITED STATES
View details

Abel Gonzalez-Perez

Co-PI

IRB Barcelona

SPAIN
View details

Theresa Lu

Professor

Weill Cornell Medical College

UNITED STATES
View details

Shruti Naik

NYU Langone Health

UNITED STATES
View details

Joaquin Mateo

Group Leader

Vall d´Hebron Institute of Oncology

SPAIN
View details

Masayuki Amagai

Professor and Chair

Keio University School of Medicine

JAPAN
View details

Christoph Ellebrecht

Hospital of the University of Pennsylvania

UNITED STATES
View details

Anthony Oro

Professor

Stanford University

UNITED STATES
View details

Yishai Levin

Lab head

Weizmann Institute of Science

ISRAEL
View details

Nuria Lopez-Bigas

ICREA Research Professor-Group Leader

Universitat Pompeu Fabra

SPAIN
View details